Advances in the treatment of neuromyelitis optic spectrum disorder
Neuromyelitis optic spectrum disorder (NMOSD) is a rare autoimmune disease characterized by recurrent episodes and severe debilitation. It primarily involves the central nervous system and is associated with the presence of aquaporin-4 antibodies. Effective management of NMOSD necessitates long-term...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864251328276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171840364806144 |
|---|---|
| author | Xiaolin Yang Shaoru Zhang Jinzhou Feng Xinyue Qin |
| author_facet | Xiaolin Yang Shaoru Zhang Jinzhou Feng Xinyue Qin |
| author_sort | Xiaolin Yang |
| collection | DOAJ |
| description | Neuromyelitis optic spectrum disorder (NMOSD) is a rare autoimmune disease characterized by recurrent episodes and severe debilitation. It primarily involves the central nervous system and is associated with the presence of aquaporin-4 antibodies. Effective management of NMOSD necessitates long-term therapeutic strategies that focus on alleviating symptoms during acute episodes and preventing relapse. In recent years, the approval of emerging biologics targeting B cells, interleukin-6 receptors, and the complement pathway has marked a transformative development in NMOSD treatment. This article provides a comprehensive review of therapeutic advances in NMOSD, integrating the current literature to serve as a theoretical basis for clinical decision-making of NMOSD patients. |
| format | Article |
| id | doaj-art-0a0cca44c87c4367bb90148deb0664ed |
| institution | OA Journals |
| issn | 1756-2864 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj-art-0a0cca44c87c4367bb90148deb0664ed2025-08-20T02:20:12ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642025-04-011810.1177/17562864251328276Advances in the treatment of neuromyelitis optic spectrum disorderXiaolin YangShaoru ZhangJinzhou FengXinyue QinNeuromyelitis optic spectrum disorder (NMOSD) is a rare autoimmune disease characterized by recurrent episodes and severe debilitation. It primarily involves the central nervous system and is associated with the presence of aquaporin-4 antibodies. Effective management of NMOSD necessitates long-term therapeutic strategies that focus on alleviating symptoms during acute episodes and preventing relapse. In recent years, the approval of emerging biologics targeting B cells, interleukin-6 receptors, and the complement pathway has marked a transformative development in NMOSD treatment. This article provides a comprehensive review of therapeutic advances in NMOSD, integrating the current literature to serve as a theoretical basis for clinical decision-making of NMOSD patients.https://doi.org/10.1177/17562864251328276 |
| spellingShingle | Xiaolin Yang Shaoru Zhang Jinzhou Feng Xinyue Qin Advances in the treatment of neuromyelitis optic spectrum disorder Therapeutic Advances in Neurological Disorders |
| title | Advances in the treatment of neuromyelitis optic spectrum disorder |
| title_full | Advances in the treatment of neuromyelitis optic spectrum disorder |
| title_fullStr | Advances in the treatment of neuromyelitis optic spectrum disorder |
| title_full_unstemmed | Advances in the treatment of neuromyelitis optic spectrum disorder |
| title_short | Advances in the treatment of neuromyelitis optic spectrum disorder |
| title_sort | advances in the treatment of neuromyelitis optic spectrum disorder |
| url | https://doi.org/10.1177/17562864251328276 |
| work_keys_str_mv | AT xiaolinyang advancesinthetreatmentofneuromyelitisopticspectrumdisorder AT shaoruzhang advancesinthetreatmentofneuromyelitisopticspectrumdisorder AT jinzhoufeng advancesinthetreatmentofneuromyelitisopticspectrumdisorder AT xinyueqin advancesinthetreatmentofneuromyelitisopticspectrumdisorder |